Krystal Biotech, Inc. (KRYS): Capital Expenditures
$11.95M
Year ended 2025-12-31
$14.56M
Trailing 12 months to 2026-06-30
-39.1%
3-year compound annual growth
-4.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.95M | +182.0% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $4.24M | -64.1% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $11.80M | -77.7% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $52.98M | -22.5% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $68.34M | +360.4% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $14.84M | +132.0% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $6.40M | +186.4% | 2021-03-01, From 2019-01-01 |
| 2018-12-31 | $2.23M | +963.8% | 2020-03-10, From 2018-01-01 |
| 2017-12-31 | $210.0K | n/m | 2018-03-12, From 2017-01-01 |
| 2016-12-31 | $15.0K | n/a | 2018-03-12, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $11.95M | +182.0% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $4.34M | -16.1% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $28.00M | +451.7% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $9.86M | +529.2% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $22.57M | +174.4% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $2.96M | -19.2% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.16M | -57.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $33.84M | +205.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $145.0K | -73.8% |
Compare KRYS, IMCR, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗